Hepatx
YC S18San Francisco, US · Founded 2015 · 4 employees · 2 known investors
HepaTx develops stem cell-based hepatocyte therapies for liver disease treatment as an alternative to organ transplantation. The company targets niche liver disease indications including alpha-1 antitrypsin deficiency, phenylketonuria, and non-alcoholic steatohepatitis.
Also known as Hepatx Corporation
Founders & leadership· Y Combinator alumni (S18)
Hepatx was founded in 2015 by Eric Schuur.
ES
Eric SchuurinFounder/CEO
Investors · 2
Competitors · 2
by search overlapTheratomeBio5 shared keywordsTheratome Bio is a regenerative medicine company using artificial intelligence to develop secretome-based therapeutics that address tissue repair and disease. The company focuses on organ transplant preservation and dry eye disease treatments.
Haya Therapeutics5 shared keywordsHAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease. The biotech company builds a regulatory genome platform to discover tissue- and cell-specific lncRNA targets and turn them into oligonucleotide-based therapies.
Companies competing with Hepatx for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $149.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Hepatx do?
- HepaTx develops stem cell-based hepatocyte therapies for liver disease treatment as an alternative to organ transplantation. The company targets niche liver disease indications including alpha-1 antitrypsin deficiency, phenylketonuria, and non-alcoholic steatohepatitis.
- Who founded Hepatx?
- Hepatx was founded by Eric Schuur in 2015.
- Who are Hepatx's investors?
- Hepatx's investors include iSelect Fund, Y Combinator.
- Where is Hepatx headquartered?
- Hepatx is headquartered in San Francisco, US.